FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and can be used for prostate cancer treatment. B IRL1620 endothelin agonist and a chemotherapeutic agent are introduced. And the chemotherapeutic agent is specified in doxorubicine and 5-fluorouracil (5-FU). Besides, there is used a product containing a composition with an active ingredient which is B IRL1620 endothelin agonist, and also the introduction instructions of the specified composition are ensured.
EFFECT: group of inventions allows to intensify prostate tumour blood supply.
13 cl, 18 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| USE OF ACYLFULVEN ANALOGS AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 1994 |
|
RU2145849C1 |
| EFFICIENT SYNTHESIS OF ETHYLENEDICYSTEINE-SUGAR CONJUGATES FOR IMAGING AND THERAPY | 2013 |
|
RU2674673C2 |
| METHOD AND COMPOSITION FOR TREATING CANCER | 2011 |
|
RU2541100C2 |
| NANOPARTICLES CARRYING CHEMOTHERAPEUTIC ANTI-CANCER THERAPEUTIC AGENT | 2012 |
|
RU2616494C2 |
| SONODYNAMIC THERAPY | 2016 |
|
RU2791572C1 |
| THERAPEUTIC USE OF THE TLR AGONIST AND COMBINED THERAPY | 2011 |
|
RU2603467C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| NANOPARTICLE BASED, TUMOUR-TARGETED DELIVERY OF MEDICINAL AGENTS | 2011 |
|
RU2593367C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
